| CTRI Number |
CTRI/2024/03/064311 [Registered on: 18/03/2024] Trial Registered Prospectively |
| Last Modified On: |
27/10/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug Ayurveda |
| Study Design |
Single Arm Study |
|
Public Title of Study
|
Ayurvedic management of Vandhyatva (female infertility) due to anovulatory factor associated with obesity |
|
Scientific Title of Study
|
Efficacy of Virechana Karma, Lashunadi Taila Matra Basti along with Guduchi-Mustadi Kashaya orally in the management of Vandhyatva (Female Infertility) due to anovulatory factor associated with obesity: A single arm open labelled clinical trial |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Alifeeya Mohammad Hussain Vaghela |
| Designation |
M.S. scholar |
| Affiliation |
Institute of Teaching and Research in Ayurveda, Jamnagar |
| Address |
Department of Prasuti Tantra Evum Stree Roga, 5th floor academic building, Institute of Teaching and Research in Ayurveda, Jamnagar
Jamnagar GUJARAT 361008 India |
| Phone |
8511607252 |
| Fax |
|
| Email |
alifeeya.vaghela@gmail.com |
|
Details of Contact Person Scientific Query
|
| Name |
Dr Shilpa B Donga |
| Designation |
Professor [I/C HOD] |
| Affiliation |
Institute of Teaching and Research in Ayurveda, Jamnagar |
| Address |
Department of Prasuti Tantra Evum Stree Roga, 5th floor academic building, Institute of Teaching and Research in Ayurveda, Jamnagar
Jamnagar GUJARAT 361008 India |
| Phone |
9825646796 |
| Fax |
|
| Email |
drshilpadonga@yahoo.com |
|
Details of Contact Person Public Query
|
| Name |
Dr Shilpa B Donga |
| Designation |
Professor [I/C HOD] |
| Affiliation |
Institute of Teaching and Research in Ayurveda, Jamnagar |
| Address |
Department of Prasuti Tantra Evum Stree Roga, 5th floor academic building, Institute of Teaching and Research in Ayurveda, Jamnagar
GUJARAT 361008 India |
| Phone |
9825646796 |
| Fax |
|
| Email |
drshilpadonga@yahoo.com |
|
|
Source of Monetary or Material Support
|
| Institute of Teaching and Research in Ayurveda, Jamnagar |
|
|
Primary Sponsor
|
| Name |
Institute of Teaching and Research in Ayurveda, Jamnagar |
| Address |
Opp.B-Division Police Station,Gurudwara Road,Jamnagar,Gujrat361008 |
| Type of Sponsor |
Research institution and hospital |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| Dr Alifeeya Mohammad Hussain Vaghela |
PG Hospital, Institute of Teaching and Research in Ayurveda, Jamnagar |
OPD no. 07,PG Hospital, Institute of Teaching and Research in Ayurveda, Jamnagar, Gujrat Jamnagar GUJARAT |
8511607252
alifeeya.vaghela@gmail.com |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| Institutional Ethics Committee, Institute of Teaching and Research in Ayurveda, Jamnagar |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition:N970||Female infertility associated withanovulation. Ayurveda Condition: VANDHYA, |
|
|
Intervention / Comparator Agent
|
| sno | Intervention/Comparator | Type | Drug-Type | Procedure Name | Details | | 1 | Intervention Arm | Procedure | - | virecana-karma, विरेचन-करà¥à¤® | (Procedure Reference: Kashyapa Samhita , Procedure details: Deepana-Pachana for 5-7 days, Snehapana until Samyaka Snigdha Lakshana is obtained, Sarvanga Abhyanga and Swedana for 4 days, Virechana Karma 1 day, Sansarjana Krama as per Shudhdhi
) (1) Medicine Name: Trivrutta Avaleha, Reference: Ashtanga Hridaya Kalpasthana Adhyaya 2, Route: Oral, Dosage Form: Avleha/Leha/Paka/Raskriya, Dose: 80(g), Frequency: od, Duration: 1 Days | | 2 | Intervention Arm | Procedure | - | mAtrAbastiH, मातà¥à¤°à¤¾à¤¬à¤¸à¥à¤¤à¤¿à¤ƒ | (Procedure Reference: Kashyapa Samhita Kalpa Sthana Adhyaya 2, Procedure details: local Abhyanga and Swedana at Kati, Adhodara and Prushtha Pradesha, Matra Basti) (1) Medicine Name: Lashunadi Taila, Reference: Kashyapa Samhita Kalpa Sthana Adhyaya 2, Route: Rectal, Dosage Form: Taila, Dose: 60(ml), Frequency: od, Duration: 7 Days | | 3 | Intervention Arm | Drug | Classical | | (1) Medicine Name: Guduchi-Mustadi Kashaya, Reference: Charaka Samhita Sutra Sthana Adhyaya 21, Route: Oral, Dosage Form: Kwatha/ Kashaya, Dose: 40(ml), Frequency: bd, Bhaishajya Kal: Abhakta, Duration: 2 Months, anupAna/sahapAna: No, Additional Information: - |
|
|
|
Inclusion Criteria
|
| Age From |
20.00 Year(s) |
| Age To |
40.00 Year(s) |
| Gender |
Female |
| Details |
Patients willing to give written informed consent by themselves.
Infertile female patients of reproductive age more than or equal to 20 years and less than or equal to 40 years.
Patients who have age less than 35 years completed active married life of minimum 1 year duration and patients aged 35 years or more completed active married life of 6 months suffering from Infertility with 2 or more consecutive anovulatory cycles.
Patients having class I obesity - overweight (BMI 25.0-29.9 kg/m2), class II obesity - obesity (BMI 30.0-39.9 kg/m2).
Primary and secondary infertile patients having anovulatory cycle or immature ovarian follicle.
Patient eligible & willing for Virechana Karma and Matra Basti.
|
|
| ExclusionCriteria |
| Details |
Patients with infectious diseases of the reproductive tract like tuberculosis and sexually transmitted diseases.
Organic lesions of the reproductive tract like carcinoma and congenital deformities.
Patients with history of cardiac diseases, Uncontrolled Diabetes (above 200 mg/dl- RBS) & Hypertension (Systolic BP above 160 & Diastolic above 100mmhg), etc.
Patients with Hepatitis C, Hepatitis B.
Patients are not eligible for Virechana Karma and Matra Basti.
|
|
|
Method of Generating Random Sequence
|
Not Applicable |
|
Method of Concealment
|
Not Applicable |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
It is expected that the trial protocol will induce ovulation.
It is expected that trial protocol will help to reduce the BMI of patient.
|
3 months |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
Trial protocol will cure menstrual abnormalities associated with anovulation like irregular, scanty/ excessive menstruation and dysmenorrhea.
Improvement in quality of life.
|
3 months |
|
|
Target Sample Size
|
Total Sample Size="20" Sample Size from India="20"
Final Enrollment numbers achieved (Total)= "21"
Final Enrollment numbers achieved (India)="21" |
|
Phase of Trial
|
Phase 3 |
|
Date of First Enrollment (India)
|
01/05/2024 |
| Date of Study Completion (India) |
27/09/2025 |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Date Missing |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Applicable |
| Recruitment Status of Trial (India) |
Completed |
Publication Details
Modification(s)
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - NO
|
|
Brief Summary
|
Introduction:The WHO defines infertility as ‘A disease of the reproductive system defined by the failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse and there is no other reason, such as breastfeeding or postpartum amenorrhoea.’ The relationship between obesity and reproductive functions has been known for many years and it is still being explored. According to American Society for Reproductive Medicine (ASRM) obesity is the cause of fertility struggle in 6% of women who have never been pregnant before. In Sthaulya, there is abnormal and excess accumulation of Medodhatu, where in only Medodhatu is nourished and other Dhatus are deprived of nourishment. According to Acharya Sushruta, Sthaulya is a Rasanimittaja Vikara and Artava being Upadhatu of Rasa Dhatu also gets affected and leads to anovulation and menstrual abnormality. In this study, Virechana Karma, Lashunadi Taila Matra Basti along with Guduchi-Mustadi Kashaya orally has been included. Virechana is effective as it works as Srotoshodhana and Kaphahara. By Virechana Karma all Srotas especially Medovaha and Rasavaha Srotas gets purified. Matra Basti given through Guda (rectal route) normalizes Apana Vayu leading to Vatanulomana and physiological functioning of Vata, which may help in turn for the extrusion of ovum from the follicle and ovulation. Guduchi-Mustadi Kashaya contains Guduchi, Musta which encounters Vata and Kapha Dosha by virtue of its Katu, Kashaya-Rasa dominance and Ushna-Veerya. Katu-Rasa performs Medo-Kledopa-Shoshana action. Triphala also having Meda-Kaphahara properties along with it enhances Agni. AIM: To evaluate the efficacy of Virechana Karma, Lashunadi Taila Matra Basti along with Guduchi-Mustadi Kashaya orally is effective in the management of female infertility due to anovulatory factor associated with obesity. OBJECTIVES: 1. To assess the efficacy of Virechana Karma, Lashunadi Taila Matra Basti along with Guduchi-Mustadi Kashaya orally on follicular growth and rupture of follicle. 2. To assess the efficacy of Virechana Karma, Lashunadi Taila Matra Basti along with Guduchi-Mustadi Kashaya orally on BMI. Materials and Methods:In the present study total 20 Clinically diagnosed and registered patients of Anovulation, fulfilling the criteria of inclusion will be registered. In 1st month, All the patients will be given Virechana Karma after the cessation of menstruation. In 2nd-3rd month Matra Basti with Lashunadi Taila 7days, after cessation of menses for 2 consecutive cycles along with Guduchi-Mustadi Kashaya (40ml) orally twice a day, before meal will be given. Results and Discussion:Data generated during the above study will be presented in a systemic manner and shall be analysed statistically. The important points of the Conceptual study, Analytical study, Pharmacological study will be discussed. Side Effects:This drug has no known unwanted effects. Adverse Drug Reaction if any observed will be reported to the Pharmacovigilance cell of I.T.R.A., Jamnagar. |